Skip to content
OpenCapital
Get started

Ionis Pharmaceuticals IONS Equity Securities (FV-NI) - Cost Basis

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiCost.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's equity securities (fv-ni) - cost basis.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's equity securities (FV-NI) - cost basis?
Ionis Pharmaceuticals (IONS) reported equity securities (FV-NI) - cost basis of $21.9M in Q1 2026.
How has Ionis Pharmaceuticals's equity securities (FV-NI) - cost basis changed year-over-year?
Ionis Pharmaceuticals's equity securities (FV-NI) - cost basis decreased by 37.5% year-over-year, from $35.01M to $21.9M.
What is the long-term trend for Ionis Pharmaceuticals's equity securities (FV-NI) - cost basis?
Over 4 years (2021 to 2025), Ionis Pharmaceuticals's equity securities (FV-NI) - cost basis has grown at a -11.6% compound annual growth rate (CAGR), from $27.51M to $16.8M.